Antioxidant drug shows promise in COVID-19 ICU patients
NCT ID NCT07374991
First seen Jan 30, 2026 · Last updated May 05, 2026 · Updated 9 times
Summary
This study tested whether the antioxidant N-Acetylcysteine (NAC) helps people with severe COVID-19 lung failure in the ICU. 59 adults were randomly assigned to receive NAC or a placebo. Researchers measured changes in inflammation and blood clotting markers, as well as survival and length of ICU stay.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gaziantep üniversity
Gaziantep, 27, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.